Immuneering (US:IMRX) ZACKSยท2024-09-16 14:15Core Insights - Immuneering Corporation (IMRX) experienced a significant stock increase of 41.3% following the release of promising early response data from an ongoing study of its drug IMM-1-104 combined with chemotherapy for pancreatic cancer [1][3]. Company Overview - IMM-1-104 is Immuneering's lead pipeline candidate, currently in a phase I/IIa study targeting advanced solid tumors with RAS mutations [2]. - The phase IIa study is assessing the 320mg dose of IMM-1-104 both as a monotherapy and in combination with chemotherapy regimens for pancreatic cancer, as well as for non-small cell lung cancer and melanoma [2]. Clinical Data - Initial results from the first five patients in the phase IIa study show a 40% initial response rate, with a disease control rate of 80% [3]. - The observed response rate of 40% is significantly higher than the benchmark overall response rate (ORR) of 23% for gemcitabine/nab-paclitaxel alone [4]. Safety and Tolerability - The combination therapy of IMM-1-104 and modified gemcitabine/nab-paclitaxel has been well tolerated among patients, maintaining a consistent safety profile [6]. Future Development Plans - The study's independent monitoring body has approved the enrollment of additional patients for the IMM-1-104 treatment arm, with new patients already beginning treatment [7]. - Immuneering expects to release initial efficacy data from at least one additional arm of the phase IIa study by the end of 2024 [8]. Market Performance - Year to date, shares of Immuneering have decreased by 72.5%, contrasting with a 0.5% growth in the industry [6].